Ticagrelor-Induced Prolongation of the QTc Interval.

IF 0.6 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS

Case Reports in Cardiology Pub Date : 2019-11-07 eCollection Date: 2019-01-01 DOI:10.1155/2019/5984847

Avik Ray, Ahmad Najmi, Gaurav Khandelwal, Balakrishnan Sadasivam

{"title":"Ticagrelor-Induced Prolongation of the QTc Interval.","authors":"Avik Ray, Ahmad Najmi, Gaurav Khandelwal, Balakrishnan Sadasivam","doi":"10.1155/2019/5984847","DOIUrl":null,"url":null,"abstract":"Background: Ticagrelor has been accepted as a class I antiplatelet agent in patients undergoing percutaneous coronary angioplasty (PTCA). There have been cases reported on ticagrelor being associated with various cardiac conduction defects. But there is no evidence of QTc prolongation associated with the drug as of yet.Case presentation: A 64-year-old male who underwent PTCA was given ticagrelor. A baseline electrocardiogram (ECG) showed a QTc of 402 ms. He returned after 1.5 months with complaints of shortness of breath. An ECG revealed a prolonged QTc of 468 ms. Ticagrelor was discontinued in view of ticagrelor-induced dyspnea and the patient was started on clopidogrel. The other medications were kept unchanged. The patient returned after a month without any complaints. A follow-up ECG showed a reduced QTc of 425 ms.Conclusion: We present a case of ticagrelor-induced QTc prolongation. To our knowledge, this is the first case to be reported on the same. The Naranjo algorithm for causality assessment gave a total score of 6 indicating that the adverse drug reaction falls under the probable category.","PeriodicalId":51760,"journal":{"name":"Case Reports in Cardiology","volume":"2019 ","pages":"5984847"},"PeriodicalIF":0.6000,"publicationDate":"2019-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2019/5984847","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Case Reports in Cardiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2019/5984847","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2019/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 3

Abstract

Background: Ticagrelor has been accepted as a class I antiplatelet agent in patients undergoing percutaneous coronary angioplasty (PTCA). There have been cases reported on ticagrelor being associated with various cardiac conduction defects. But there is no evidence of QTc prolongation associated with the drug as of yet.

Case presentation: A 64-year-old male who underwent PTCA was given ticagrelor. A baseline electrocardiogram (ECG) showed a QTc of 402 ms. He returned after 1.5 months with complaints of shortness of breath. An ECG revealed a prolonged QTc of 468 ms. Ticagrelor was discontinued in view of ticagrelor-induced dyspnea and the patient was started on clopidogrel. The other medications were kept unchanged. The patient returned after a month without any complaints. A follow-up ECG showed a reduced QTc of 425 ms.

Conclusion: We present a case of ticagrelor-induced QTc prolongation. To our knowledge, this is the first case to be reported on the same. The Naranjo algorithm for causality assessment gave a total score of 6 indicating that the adverse drug reaction falls under the probable category.

Abstract Image

查看原文本刊更多论文

替格瑞洛诱导的QTc间期延长。

背景:替格瑞洛已被接受为经皮冠状动脉成形术(PTCA)患者的I类抗血小板药物。有病例报道，替格瑞洛与各种心脏传导缺陷有关。但目前还没有证据表明QTc延长与该药有关。病例介绍:一位接受PTCA的64岁男性给予替格瑞洛。基线心电图(ECG)显示QTc为402 ms。1个半月后，他回到医院，主诉呼吸短促。心电图显示QTc延长468毫秒。考虑到替卡格雷引起的呼吸困难，停用替卡格雷，患者开始使用氯吡格雷。其他药物保持不变。一个月后病人回来了，没有任何不适。随访心电图显示QTc减少425 ms。结论:我们报告了一例替格瑞洛致QTc延长。据我们所知，这是在同一地点报告的首例病例。因果关系评估的Naranjo算法给出的总分为6分，表明该药物不良反应属于可能类别。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Case Reports in Cardiology CARDIAC & CARDIOVASCULAR SYSTEMS-

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Case Reports in Cardiology is a peer-reviewed, Open Access journal that publishes case reports and case series related to hypertension, arrhythmia, congestive heart failure, valvular heart disease, vascular disease, congenital heart disease and cardiomyopathy.